BioCentury | Jan 18, 2020
Product Development

Mapping the path to gene therapy 2.0

...to a single dose. Two in vivo gene therapies have been approved since 2017. Luxturna voretigene neparvovec-rzyl...
BioCentury | Dec 23, 2019
Company News

Roche’s ex-U.S. deal for Sarepta DMD programs could extend beyond micro-dystrophin gene therapy

...that closed last week. With that, Roche took possession of marketed ophthalmic gene therapy Luxturna voretigene neparvovec-rzyl...
BioCentury | Dec 21, 2019
Product Development

It’s been a hell of a millennium -- and it’s just getting started

...therapies like Luxturna voretigene neparvovec-rzyl from Spark Therapeutics Inc., now a part of Roche (SIX:ROG; OTCQX:RHHBY). Luxturna...
BioCentury | Dec 13, 2019
Finance

NanoDimension backs sight-restoring therapy developer Arctos in series A

...other disorders--a much broader group than those served by sight-restoring gene therapies such as Luxturna voretigene neparvovec-rzyl...
BioCentury | Dec 5, 2019
Finance

With $75M from Apple Tree, Limelight seeks to overcome limitations of genetic therapy

...the Children’s Hospital of Philadelphia (CHOP). Both were instrumental in the early development of Luxturna voretigene neparvovec...
BioCentury | Sep 24, 2019
Company News

Cigna eases burden of high cost gene therapies; plan doesn’t account for lack of benefit

...Zolgensma onasemnogene abeparvovec-xioi from the AveXis unit of Novartis AG (NYSE:NVS; SIX:NOVN) and Luxturna voretigene neparvovec-rzyl...
...to treat spinal muscular atrophy (SMA) and carries a wholesale acquisition cost of $2.125 million. Luxturna...
...qualifies for treatment. Without the benefit, said Luddy, plans with coverage policies for Zolgensma or Luxturna...
BioCentury | Sep 4, 2019
Company News

Novartis’ early collaboration with NICE key to rapid response on Luxturna

...therapy to receive a positive recommendation, Strimvelis from Orchard Therapeutics plc (NASDAQ:ORTX). NICE reviewed Luxturna voretigene neparvovec...
...has rights from Spark Therapeutics Inc. (NASDAQ:ONCE) to develop and commercialize Luxturna outside the U.S. Luxturna...
...months, or 28 weeks (see " NICE Recommends Strimvelis "). Erin McCallister, Senior Editor AAV2-hRPE65v2, Luxturna, voretigene neparvovec-rzyl (spk-rpe65) National...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...that only two came in below analyst consensus estimates in 1Q19. Ophthalmic gene therapy Luxturna voretigene neparvovec-rzyl...
...$0.5 NA Spark Therapeutics Inc. (NASDAQ:ONCE) Granted ex-U.S. rights to Novartis AG (NYSE:NVS; SIX:NOVN) Luxturna voretigene neparvovec-rzyl...
BioCentury | Jun 27, 2019
Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

...data expected this year. Two in vivo gene therapies have been approved since 2017, Luxturna voretigene neparvovec-rzyl...
...therapy Zolgensma onasemnogene abeparvovec-xioi at $2,125 million for a one-time therapy; Spark Therapeutics Inc.'s Luxturna voretigene neparvovec-rzyl...
BioCentury | Jun 17, 2019
Company News

Trial data suggest 80% of Zynteglo patients could meet milestones in outcomes-based pricing model

...untreated. Spark Therapeutics Inc. (NASDAQ:ONCE), which is being acquired by Roche (SIX:ROG; OTCQX:RHHBY), priced Luxturna voretigene neparvovec-rzyl...
...has previously estimated a prevalence of 3,500 patients in the U.S. and Europe eligible for Luxturna...
Items per page:
1 - 10 of 113